Sunitinib-platinum (IV) prodrug-1

Sunitinib-platinum (IV) prodrug-1 (Complex A) is a Pt (IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt (IV) to be reduced to active Pt (II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum (IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum (IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum (IV) prodrug-1 can be used for research on renal cell carcinoma[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; DNA Alkylator/Crosslinker; PDGFR; VEGFR

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

CC1=C(C(C)=C(N1)/C=C2C(NC3=C\2C=C(C=C3)F)=O)C(NCCCC(O[Pt](N)(O)(Cl)(Cl)N)=O)=O

Molecular Formula

C20H24Cl2FN5O5Pt

Molecular Weight

699.42

References & Citations

[1]Beirne DF, et al. Pt (IV) Prodrugs Bearing Sunitinib-Derived Ligands Display Exceptional Anticancer Activity against Renal Cell Carcinoma When Compared to Conventional Platinum Chemotherapy. J Med Chem. 2025 Nov 27;68 (22) :24294-24304.